Lorenzo Tallarigo Buys 22,066 Shares of Oxford BioMedica plc (OXB) Stock

Posted by Logan Wallace on Mar 24th, 2018 // Comments off

Oxford BioMedica plc (LON:OXB) insider Lorenzo Tallarigo acquired 22,066 shares of the business’s stock in a transaction dated Thursday, March 22nd. The shares were purchased at an average price of GBX 12 ($0.17) per share, with a total value of £2,647.92 ($3,658.36).

Lorenzo Tallarigo also recently made the following trade(s):

How to Become a New Pot Stock Millionaire

On Friday, February 23rd, Lorenzo Tallarigo acquired 22,121 shares of Oxford BioMedica stock. The shares were purchased at an average price of GBX 12 ($0.17) per share, with a total value of £2,654.52 ($3,667.48).

OXB stock opened at GBX 11.30 ($0.16) on Friday. Oxford BioMedica plc has a 12-month low of GBX 4.44 ($0.06) and a 12-month high of GBX 13.19 ($0.18).

Separately, Peel Hunt restated a “buy” rating and set a GBX 13 ($0.18) price objective on shares of Oxford BioMedica in a research report on Thursday, February 1st.

ILLEGAL ACTIVITY NOTICE: “Lorenzo Tallarigo Buys 22,066 Shares of Oxford BioMedica plc (OXB) Stock” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3294465/lorenzo-tallarigo-buys-22066-shares-of-oxford-biomedica-plc-oxb-stock.html.

About Oxford BioMedica

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.

Insider Buying and Selling by Quarter for Oxford BioMedica (LON:OXB)

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.